EP0915848A1 - 1,2-diarylindoles en tant qu'inhibiteurs de cox-2 - Google Patents
1,2-diarylindoles en tant qu'inhibiteurs de cox-2Info
- Publication number
- EP0915848A1 EP0915848A1 EP97936720A EP97936720A EP0915848A1 EP 0915848 A1 EP0915848 A1 EP 0915848A1 EP 97936720 A EP97936720 A EP 97936720A EP 97936720 A EP97936720 A EP 97936720A EP 0915848 A1 EP0915848 A1 EP 0915848A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- lower alkyl
- carbon atoms
- alkyl radical
- radical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates, as new products, to the 1,2-diarylindole derivatives of general formula (I).
- cyclooxygenase route One of the biotransformation routes of arachidonic acid is the cyclooxygenase route; it allows the transformation of arachidonic acid into PGG2 and then into PGH2.
- cyclooxygenase-1 COX-1
- COX-2 cyclooxygenase 2
- the first is a constitutive enzyme, expressed in most tissues, while the second which is expressed in some tissues such as the brain, is inducible in most tissues by many products, in particular by cytokines and mediators produced in during the inflammatory reaction.
- Each enzyme plays a different role and the inhibition of
- COX-1 or COX-2 will cause consequences that are not identical. Inhibition of COX-1 will cause a decrease in prostaglandins participating in homeostasis which can lead to side effects. Inhibition of COX-2 will cause a decrease in the prostaglandins produced in an inflamed situation. Thus the selective inhibition of COX-2 makes it possible to obtain a well-tolerated anti-inflammatory agent.
- the compounds of the invention make it possible to obtain this selective inhibition. Consequently, the compounds in question have a very interesting phaimacological profile insofar as they are endowed with anti-inflammatory and analgesic properties while being remarkably well tolerated in particular at the gastric level. They will be particularly indicated for the treatment of inflammatory phenomena and for the treatment of pain.
- Mention may be made, for example, of their use in the treatment of arthritis, in particular rheumatoid arthritis, spondylarthritis, gout arthritis, osteoarthritis, juvenile arthritis, autoimmune diseases, lupus erythematous. They will also be indicated for the treatment of bronchial asthma, dysmenorrhea, tendinitis, bursitis, dermatological inflammations such as pso ⁇ asis, eczema, burns, dermatitis. They can also be used for the treatment of gastrointestinal inflammations, Crohn's disease. stomachs, ulcerative colitis, cancer prevention, including adenocarc ome of the colon, prevention of neurodegenerative diseases especially Alzheimer's disease, prevention of Stroke, epilepsy and prevention of premature labor.
- the present invention also relates to the process for the preparation of said products and their applications in therapy.
- indole derivatives are described for their application as inhibitors of cyclooxygenase-2 in US Pat. No. 5,510,368 to Merck Frosst. These derivatives are very different in terms of their chemical structure from the compounds claimed by the applicant since they are indole derivatives substituted in position-2 with a methyl group, unlike the compounds of the invention which are substituted in position-2 by an aryl group.
- the compounds described in this prior document all comprise in position 3 an alkyl chain with an ester or acid function which is not found in any of the compounds of the invention.
- in position-1 these compounds still move away from the compounds of the invention since it is always a benzyl group and not an aryl group.
- Derivatives diarylindole-1.2 according to the invention are characterized in that they correspond to the general formula (I):
- R represents: - a lower alkyl radical of 1 to 6 carbon atoms
- A represents:
- and X 2 independently represent - the hydrogen atom, - a halogen atom, - a lower alkyl radical of 1 to 6 carbon atoms,
- -n is an integer from 0 to 2
- - Ri and R 2 independently represent the hydrogen atom or a lower alkyl radical of 1 to 6 carbon atoms
- A can also represent a heterocycle thiophene, furan, py ⁇ dine or pyrimidine
- Y ⁇ and Y 2 independently represent:
- R' representing the hydrogen atom or a lower alkyl radical of 1 to 6 carbon atoms
- Y 3 represents. - the hydrogen atom
- lower alkyl means a hydrocarbon chain having from 1 to 6 carbon atoms, linear or branched.
- a lower alkyl radical is, for example, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiobutyl, pentyl, isopentyl, hexyl, isohexyl radical.
- lower haloalkyl radical is meant an alkyl radical of 1 to 6 carbon atoms of which 1 to 7 hydrogen atoms have been substituted with 1 to 7 halogen atoms.
- a lower haloalkyl radical is for example a trifluoromethyl radical, a t ⁇ fluoro-2,2,2 ethyl radical, a pentafluoroethyl radical, a 2,2-difluoro-trifluoro 3.3.3 propyl radical, a heptafluoropropyl radical. a chloromethyl or bromomethyl radical.
- Halogen means a chlorine, bromine, iodine or fluorine atom.
- the derivatives in accordance with the invention are the derivatives of formula (I) mentioned above in which:
- R represents:
- Y A represents an aromatic nucleus
- -n is equal to 0 or 1
- - i and R 2 represent a lower alkyl radical of 1 to 6 carbon atoms, or also X, and X 2 together form a methylene dioxy group
- A represents a heterocycle thiophene, pyridine or pyrimidine Y
- Y 2 independently represent: - the hydrogen atom
- Y represents: - the hydrogen atom
- R represents a methyl radical or an NH 2 group
- - A represents an aromatic nucleus
- - X represents the hydrogen atom, the fluorine atom, the chlorine atom, a methyl radical or an N (CH 3 ) 2 radical, - X represents the hydrogen atom,
- the particularly preferred compounds of the invention are the following compounds:
- Y ,, Y 2 and Y 3 are defined as above and R'represents an alkyl radical lower than 1 to 6 atoms or a haloalkyl radical lower than 1 to 6 carbon atoms, by reaction with the compounds of formula (III) AX
- A represents an aromatic nucleus
- X, and X 2 are defined as above or a heterocycle thiophene furan, pyridine or pyrimidine, and where X represents a halogen atom, according to the conditions determined in the literature, illustrated for example by the following references: Khan ,MY; Rocha.EK Chem Pharm Bull 1977. 31 10.
- Y 3 , and A are defined as above, and where R represents the methyl group
- Y 3 and R ′ are defined as above by oxidation reaction with a peracid such as m-chloroperbenzoic acid in an organic solvent such as dichloromethane or with a mineral oxidizing agent such as potassium permanganate or sodium perborate in a solvent such as acetic acid.
- a peracid such as m-chloroperbenzoic acid
- organic solvent such as dichloromethane
- mineral oxidizing agent such as potassium permanganate or sodium perborate in a solvent such as acetic acid.
- Y 3 is defined as above.
- the acetophenone compounds of formula (VII) may also be obtained by the method described in Organic Synthesis Coll. Flight. 4, 1963, p. 708 from the acids known in the literature and of formula (X),
- This method consists in reacting the chloride of the acids of formula (X) with 1 ethoxymagnesiumdiethylmalonate.
- Another mode of preparation of the compounds of the invention of formula (I) consists in carrying out the dehydrogenation of derivatives of formula (XI) in which A, Y ,, Y 2 , Y 3 and R have the same meaning as above .
- This dehydrogenation is carried out for a period ranging from a few hours to several days in the presence of a catalyst such as 10% Pd / C in an organic solvent such as mesitylene and at temperatures ranging from room temperature to 250 ° C.
- a catalyst such as 10% Pd / C in an organic solvent such as mesitylene and at temperatures ranging from room temperature to 250 ° C.
- the compounds of formula (I) as defined above are inhibitors of cyclooxygenase-2 and are endowed with a very good anti-inflammatory and analgesic activity associated with an excellent tolerance in particular gastric.
- the invention also covers a pharmaceutical composition, characterized in that it comprises a pharmaceutically effective amount of at least one compound of formula (I) as previously defined optionally incorporated in a pharmaceutically acceptable excipient, vehicle or support.
- compositions can be administered by the oral, rectal, parenteral, transdermal, ocular, nasal or auricular route.
- These compositions can be solid or liquid and can be presented in the pharmaceutical forms commonly used in human medicine such as, for example, simple or coated tablets, capsules, granules, suppositories, injectables, transdermal systems, eye drops, aerosols and sprays and ear drops. They are prepared according to the usual methods.
- the active principle consisting of a pharmaceutically effective amount of at least one compound of formula (I) defined as above, can be incorporated therein into excipients usually employed in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, polyvidone, cellulose derivatives, cocoa butter, semi-synthetic glycerides, vehicles aqueous or not, fatty substances of animal or vegetable origin, glycols, various wetting agents, dispersants or emulsifiers, silicone gels, certain polymers or copolymers, preservatives, flavors and colors.
- excipients usually employed in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, polyvidone, cellulose derivatives, cocoa butter, semi-synthetic glycerides, vehicles aqueous or not, fatty substances of animal or vegetable origin, glycols, various wetting agents, dispersants or emulsifiers, silicone
- the invention also covers a pharmaceutical composition with anti-inflammatory and analgesic activity making it possible in particular to favorably treat inflammatory phenomena and pain, characterized in that it comprises a pharmaceutically effective amount of at least one compound of formula (I) optionally mentioned above. incorporated in a pharmaceutically acceptable excipient, vehicle or support.
- a pharmaceutical composition with anti-inflammatory and analgesic activity is prepared, making it possible in particular to favorably treat the various inflammations and pain.
- the invention also covers a pharmaceutical composition useful in the prevention of cancer, in particular colon adenocarcinoma, the prevention of neurodegenerative diseases, particularly Alzheimer's disease, the prevention of Stroke, epilepsy and the prevention of premature uterine labor. .
- a composition is prepared formulated in the form of capsules or tablets dosed from 1 mg to 1000 mg or in the form of injectable preparations dosed from 0.1 mg to 500 mg.
- Formulations in the form of suppositories, ointments, creams, gels, aerosol preparations, transdermal preparations or plasters may also be used.
- the invention also covers a method of therapeutic treatment of mammals, characterized in that a therapeutically effective amount of at least one compound of formula (I) as defined above is administered to this mammal.
- the compound of formula (I) either alone or in combination with a pharmaceutically acceptable excipient, is formulated in capsules or tablets dosed from 1 mg to 1000 mg for administration by orally, or in the form of injectable preparations dosed from 0.1 mg to 500 mg or also in the form of suppositories, ointments, creams, gels or aerosol preparations. This process allows in particular to favorably treat inflammatory phenomena and pain.
- the compounds of formula (I) can be administered alone or in combination with a physiologically acceptable excipient in any form, in particular orally in the form of capsules or tablets or parenterally in the form of an injectable solution .
- a physiologically acceptable excipient in any form, in particular orally in the form of capsules or tablets or parenterally in the form of an injectable solution .
- Other forms of administration such as suppositories, ointments, creams, gels or aerosol preparations can be considered.
- the compounds according to the invention can be administered in human therapy in the abovementioned indications by oral route in the form of tablets or capsules dosed from 1 mg to 1000 mg or parenterally in the form of injections dosed from 0.1 mg to 500 mg in one or more daily doses for an adult of average weight 60 to 70 kg.
- the usable daily dose is between
- the white solid obtained is purified by recrystallization from water to give 46.9 g of 4- (methylsulfonyl) fluorobenzene.
- Example 2b 4- (methylsulfonyl) acetopbenone
- Example 2d 4- (methyl_sulfonyl) acetophenone
- Example 2c and 2d According to the procedure of Example 2c and 2d and using the appropriate acid chloride, the compound of Example 3 was prepared.
- Example 7 4- (methylsulfonyl) acetophenone 4- (methylsulfonyl) phenyl hydrazone
- Example 8 1- [4- (methylsuIfonyl) phenyl] propanone phenyl hydrazone
- Example 9 4- ( ⁇ _é_hylsulfonyl) acetophenone 3,5-dichlorophenyl hydrazone
- Example 10 4- (methylsulfonyl) acetophenone (4-methylphenyl) hydrazone
- Example 11 4- (methylsulfonyl) acetophenone (4-fluorophenyl) hydrazone
- Example 12 4- (methylsulfonyl acetophenone) -2,4-difluorophényi hydrazone
- a second jet of 34.1 g can be obtained by concentrating the mother liquors.
- Example 13 According to Example 13 and using the appropriate hydrazones, the compounds of Examples 14 to 20 were prepared.
- Empirical formula C 16 H 15 NO 4 S 2 Melting point: 325 ° C.
- Example 16 3-methyl-2- [4- (methylsulfonyl) phe ⁇ yI] indole
- Boiling point 106 ° C under about 20 mmHg.
- Example 22 the compound of Example 23 was prepared.
- Example 25 1- (4-fluorophenyl) -2- (4-methanesulfo ⁇ ylphenyl) -4,5,6,7- tetrahydro- 1 H-indole
- Example 28 1- (3-hydroxyphenyl) -2- (4-methanesulfonylphenyl) -4,5,6,7- tetrahydro-1H-indole
- Example 30 1- (3,4-dichlorophenyl) -2- (4-methanesulfonylphenyl) -4,5,6,7- tetrahydro- 1 H-indole
- Example 31 l- (4 -__ uorophenyl) -2- [4- (méthy.sulfonyIphényI)] indole
- the product is purified a first time by chromatography on silica gel (eluent CH 2 C1 2 98% / ethyl acetate 2%) then recrystallized from 2-methoxy ethanol to give 4.1 g of l-Benzo [1, 3] dioxol-5-yl-2- (4-methylsulfonyl phenyl) indole.
- a mixture of 3 g of 1- (3,4-dichlorophenyl) -2- ( 4-methanesulfonylphenyl) -4,5,6,7-tetrahydro-1 H-indole prepared in the example is heated at 80 ° C. for 15 h. 30.
- Example 36 1- (4-chlorophenyl) -2- [4- (methylsulfonyl) phenyl] indole
- Example 39 1- [4- (N, N-dimethylaminomethyl) phenyl] -2- [4- (methylsulfonyl) phenyljindole
- Example 41 1- [4- (N, N-dimethylaminomethyl) phenyl] -3-methyl-2- [4- (methylsulfonyl) phenyljindole
- Example 45 _- [4- (N, N-dimethylaminomethyl) phenyl] -5-methyl-2- [4- (methylsulfonyl) phenyl] indole
- Example 47 1- [4- (N, N-dimethylaminophenyl) 1- 2- [4- (methylsulfonyl) phenyl] indole hydrochloride
- the base was purified by two successive silica gel chromatographies (eluent CH 2 C1 2 and 80% toluene / 20% ethyl acetate). Recrystallized from 2-methoxyethanol.
- Example 52 1- (3-chlorophenylj-2- [4- (methylsulfonyl) phenyl] indole
- Example 54 1- (4-methoxyphenyl) -2- ⁇ 4- (methylsulfonyl) phenyl] indole
- the studied molecule is preincubated for 10 minutes at 25 ° C with 2U of COXl (purified enzyme from seminal vesicles of ram) or 1U of COX2 (purified enzyme from sheep placenta).
- Arachidonic acid (6 ⁇ M for COXl. 4 ⁇ M for COX2) is added to the reaction medium and an incubation of 5 minutes at 25 ° C is carried out. At the end of the incubation, the enzymatic reaction is stopped by adding HCI IN and the PGE2 produced is assayed by EIA.
- results are expressed in the form of a percentage inhibition of the COXl and COX2 enzymatic activities, and correspond to means ⁇ standard deviations from the movenne of 4 determinations.
- the first toxicology studies carried out show that the products of the examples do not induce any deleterious effect after oral absorption in rats at doses up to 300 mg / kg.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9609741 | 1996-08-01 | ||
FR9609741A FR2751966B1 (fr) | 1996-08-01 | 1996-08-01 | Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique |
PCT/FR1997/001432 WO1998005639A1 (fr) | 1996-08-01 | 1997-07-31 | 1,2-diarylindoles en tant qu'inhibiteurs de cox-2 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0915848A1 true EP0915848A1 (fr) | 1999-05-19 |
Family
ID=9494743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97936720A Ceased EP0915848A1 (fr) | 1996-08-01 | 1997-07-31 | 1,2-diarylindoles en tant qu'inhibiteurs de cox-2 |
Country Status (7)
Country | Link |
---|---|
US (1) | US5723485A (fr) |
EP (1) | EP0915848A1 (fr) |
JP (1) | JP2000515162A (fr) |
AU (1) | AU729386B2 (fr) |
CA (1) | CA2261783A1 (fr) |
FR (1) | FR2751966B1 (fr) |
WO (1) | WO1998005639A1 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6649645B1 (en) * | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
DE19951360A1 (de) * | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
PL351944A1 (en) * | 1999-12-08 | 2003-07-14 | Pharmacia Corp | Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
US6353007B1 (en) * | 2000-07-13 | 2002-03-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents |
WO2002005848A2 (fr) * | 2000-07-13 | 2002-01-24 | Pharmacia Corporation | Utilisation d'inhibiteurs de cox-2 pour le traitement et la prevention de troubles oculaires a mediation cox-2 |
PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
US7695736B2 (en) | 2001-04-03 | 2010-04-13 | Pfizer Inc. | Reconstitutable parenteral composition |
WO2002100339A2 (fr) * | 2001-06-13 | 2002-12-19 | Biogal Gyogyszergyar Rt. | Nouveau procede pour la preparation de rac-bicalutamide et des produits intermediaires de celui-ci |
US7102026B2 (en) | 2001-06-13 | 2006-09-05 | Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság | Process for preparing and isolating rac-bicalutamide and its intermediates |
UA80682C2 (en) * | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
PL1745791T3 (pl) | 2003-05-07 | 2013-11-29 | Osteologix As | Leczenie chorób chrząstki/kości za pomocą rozpuszczalnych w wodzie soli strontu |
JP2007523873A (ja) * | 2003-07-15 | 2007-08-23 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
AU2005294404A1 (en) * | 2004-10-04 | 2006-04-20 | Myriad Genetics, Inc. | Compounds for Alzheimer's disease |
DOP2006000016A (es) * | 2005-01-26 | 2006-07-31 | Aventis Pharma Inc | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2. |
CN100543015C (zh) * | 2005-10-28 | 2009-09-23 | 中国人民解放军军事医学科学院毒物药物研究所 | 环氧合酶-2选择性抑制剂及其医药用途 |
JP2010516679A (ja) * | 2007-01-19 | 2010-05-20 | マリンクロット インコーポレイテッド | 診断用および治療用シクロオキシゲナーゼ−2結合リガンド |
US7947723B2 (en) | 2008-02-01 | 2011-05-24 | Spelman College | Synthesis and anti-proliferative effect of benzimidazole derivatives |
CA3209491A1 (fr) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Dipalmitoyl-phosphatidyl-ethanol-amine conjuguee a l'acide hyaluronique en combinaison avec des medicaments anti-inflammatoires non steroidiens (ains) pour traiter ou soulager des maladies inflammatoire |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950701317A (ko) * | 1992-05-08 | 1995-03-23 | 오오쓰까 아끼히꼬 | 인돌 유도체(Indole Derivative) |
US5521213A (en) * | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5510368A (en) * | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
-
1996
- 1996-08-01 FR FR9609741A patent/FR2751966B1/fr not_active Expired - Fee Related
- 1996-10-07 US US08/723,450 patent/US5723485A/en not_active Expired - Fee Related
-
1997
- 1997-07-31 JP JP10507674A patent/JP2000515162A/ja active Pending
- 1997-07-31 WO PCT/FR1997/001432 patent/WO1998005639A1/fr not_active Application Discontinuation
- 1997-07-31 CA CA002261783A patent/CA2261783A1/fr not_active Abandoned
- 1997-07-31 AU AU39444/97A patent/AU729386B2/en not_active Ceased
- 1997-07-31 EP EP97936720A patent/EP0915848A1/fr not_active Ceased
Non-Patent Citations (1)
Title |
---|
See references of WO9805639A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU3944497A (en) | 1998-02-25 |
AU729386B2 (en) | 2001-02-01 |
JP2000515162A (ja) | 2000-11-14 |
CA2261783A1 (fr) | 1998-02-12 |
FR2751966B1 (fr) | 1998-10-30 |
US5723485A (en) | 1998-03-03 |
WO1998005639A1 (fr) | 1998-02-12 |
FR2751966A1 (fr) | 1998-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0915848A1 (fr) | 1,2-diarylindoles en tant qu'inhibiteurs de cox-2 | |
CZ274996A3 (en) | Heterocyclic aromatic oxazole compounds, their oxime, ketone, ketonemethylene, ester and amide compounds, pharmaceutical preparations, cyclooxygenase inhibitors and antiphlogistic agents in which said oxazole compounds are comprised | |
WO2002081453A1 (fr) | Hiohydantoïnes et leur utilisation dans le traitement du diabete | |
EP1254134B1 (fr) | Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands pour les recepteurs v1b ou v1b et v1a de l'arginine-vasopressine | |
EP1259505B1 (fr) | Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b ou v1b et v1a de l'arginine-vasopressine | |
EP1296976B1 (fr) | Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b et v1a de l'arginine-vasopressine | |
FR2658511A1 (fr) | Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant. | |
FR2567885A1 (fr) | Derives 3-aminopropoxyaryliques, leur preparation, leur application comme medicaments et compositions pharmaceutiques les contenant | |
WO1997000868A1 (fr) | Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant | |
JP2010533645A (ja) | 脂肪酸アミドヒドロラーゼの三環系阻害剤 | |
FR2753449A1 (fr) | Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique | |
EP0611766A1 (fr) | Dérivés de 2-amido-thiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament | |
EP1023277A1 (fr) | Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique | |
FR2751964A1 (fr) | Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique | |
EP0109866B1 (fr) | Nouveaux dérivés de la sulfonylurée, leurs procédés de préparation et les compositions pharmaceutiques les renfermant | |
EP0891345B1 (fr) | Nouveaux derives diarylmethylidene furaniques, leurs procedes de preparation et leurs utilisations en therapeutique | |
WO1991019714A1 (fr) | Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent | |
EP0395528B1 (fr) | Dérivés du 4-phénylméthyl 1H-indole, procédé et intermédiaires de préparation, application à titre de médicaments et compositions les renfermant. | |
FR2775477A1 (fr) | Nouveaux derives diarylmethylene heterocycliques, leurs procedes de preparation et leurs utilisations en therapeutique | |
EP0463944A1 (fr) | Acyl benzoxazolinones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
EP0705261A1 (fr) | Naphtyridines antiproliferatives | |
EP0382618A2 (fr) | Dérivés aminoalkoxyphényle, leur procédé de préparation ainsi que les compositions en contenant | |
EP0382628A1 (fr) | Dérivés aminoalkoxyphényle, leur procédé de préparation ainsi que les compositions en contenant | |
FR2754256A1 (fr) | Nouveaux derives 1,2-diarylmethylenes, leurs procedes de preparation, et leurs utilisations en therapeutique | |
EP0209435A1 (fr) | Dérivés de l'hydroxy alkoxy 4-phénylpropyl indole, leurs sels, procédé et intermédiaires de préparation, application à titre de médicaments et compositions les renfermant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990114 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 19990114;LT PAYMENT 19990114;LV PAYMENT 19990114;RO PAYMENT 19990114;SI PAYMENT 19990114 |
|
17Q | First examination report despatched |
Effective date: 20010611 |
|
APBT | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9E |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
18R | Application refused |
Effective date: 20050721 |